In general, the three cell lines with CREBBP and/or EP300 mutations showed a higher sensitivity than the two wild-type cell lines for these genes (OCILY3 and U2932) (Fig. 5C), suggesting that dependency of the remaining HAT function is a druggable vulnerability in DLBCL cells with either CREBBP or EP300 genetic alterations (Fig. 5D). The gene discussed is CREBBP; the disease is diffuse large B-cell lymphoma.